Metrochem API Private Limited Metrochem API Private Limited

X

CAS 885340-13-6 manufacturers and suppliers on PharmaCompass

PharmaCompass
CAS 885340-13-6
Also known as: 885340-13-6, 1-(3-hydroxypropyl)-5-[(2r)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carbonitrile, Schembl526322, 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]-ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carbonitrile, 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carbonitrile, 1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]indoline-7-carbonitrile
Molecular Formula
C25H30F3N3O3
Molecular Weight
477.5  g/mol
InChI Key
BJOFTYXQHZTKMG-GOSISDBHSA-N

1 2D Structure

CAS 885340-13-6

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carbonitrile
2.1.2 InChI
InChI=1S/C25H30F3N3O3/c1-18(30-8-12-33-22-5-2-3-6-23(22)34-17-25(26,27)28)13-19-14-20-7-10-31(9-4-11-32)24(20)21(15-19)16-29/h2-3,5-6,14-15,18,30,32H,4,7-13,17H2,1H3/t18-/m1/s1
2.1.3 InChI Key
BJOFTYXQHZTKMG-GOSISDBHSA-N
2.1.4 Canonical SMILES
CC(CC1=CC2=C(C(=C1)C#N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
2.1.5 Isomeric SMILES
C[C@H](CC1=CC2=C(C(=C1)C#N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 885340-13-6

2. 1-(3-hydroxypropyl)-5-[(2r)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carbonitrile

3. Schembl526322

4. 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]-ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carbonitrile

5. 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carbonitrile

6. 1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]indoline-7-carbonitrile

2.3 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 477.5 g/mol
Molecular Formula C25H30F3N3O3
XLogP34.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count12
Exact Mass477.22392631 g/mol
Monoisotopic Mass477.22392631 g/mol
Topological Polar Surface Area77.8 Ų
Heavy Atom Count34
Formal Charge0
Complexity656
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Flag India
Digital Content Digital Content
URL Supplier Web Content
160969-03-9
Silodosin
Ocimum Labs was founded in 2018 and started its R&D activities with a cutting-edge facility. The Hyderaba...
Ocimum Labs was founded in 2018 and started its R&D activities with a cutting-edge facility. The Hyderabad-based firm focuses on process research and development, with a particular emphasis on choosing an API portfolio with a wide range of applications for the global pharma market. It provides a wide variety of integrated products and services. By offering timely and high-quality support, Ocimum Labs hopes to become a strategic partner to global pharma firms and deliver high-quality, cost effective key starting materials, intermediates and APIs. It intends to build a manufacturing facility with a 230KL capacity in Visakhapatnam, India.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag India
Digital Content Digital Content
URL Supplier Web Content
459868-73-6
Silodosin
Ocimum Labs was founded in 2018 and started its R&D activities with a cutting-edge facility. The Hyderaba...
Ocimum Labs was founded in 2018 and started its R&D activities with a cutting-edge facility. The Hyderabad-based firm focuses on process research and development, with a particular emphasis on choosing an API portfolio with a wide range of applications for the global pharma market. It provides a wide variety of integrated products and services. By offering timely and high-quality support, Ocimum Labs hopes to become a strategic partner to global pharma firms and deliver high-quality, cost effective key starting materials, intermediates and APIs. It intends to build a manufacturing facility with a 230KL capacity in Visakhapatnam, India.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag India
Digital Content Digital Content
URL Supplier Web Content
239463-85-5
Silodosin
Ocimum Labs was founded in 2018 and started its R&D activities with a cutting-edge facility. The Hyderaba...
Ocimum Labs was founded in 2018 and started its R&D activities with a cutting-edge facility. The Hyderabad-based firm focuses on process research and development, with a particular emphasis on choosing an API portfolio with a wide range of applications for the global pharma market. It provides a wide variety of integrated products and services. By offering timely and high-quality support, Ocimum Labs hopes to become a strategic partner to global pharma firms and deliver high-quality, cost effective key starting materials, intermediates and APIs. It intends to build a manufacturing facility with a 230KL capacity in Visakhapatnam, India.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY